HIV Therapeutics Market to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth
The leading business intelligence provider GBI Research has released its latest research report, entitled “HIV Therapeutics Market to 2019 – Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth”. The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research found that the HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012–2019 forecast period to reach $16.3 billion.
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/hiv-therapeutics-market-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-market-growth
Scope
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV.
The report covers and includes:
• A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and diagnosis
• In-depth analysis of major glucose-lowering drugs for HIV, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
• Comprehensive review of the pipeline for HIV therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
• Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy, Spain and Canada
• Discussion of the drivers and barriers for market growth
Reasons to Buy
Browse Full Report With TOC: http://www.marketresearchreports.biz/sample/sample/193009
The report will enhance your decision-making capability. It will allow you to:
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
• Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
• Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Route of HIV Transmission
2.3 Etiology
2.4 Classification of HIV-1 Subtypes
2.5 Pathophysiology 12
2.5.1 HIV-1 Replication Cycle
2.5.2 Mechanism of CD4 T-Cell Death
2.5.3 Latent Infection and Viral Persistence
2.6 Symptoms
2.7 Diagnosis
2.7.1 HIV Antibody Assay
2.7.2 Rapid HIV Antibody Test
2.7.3 Western Blot
2.7.4 HIV p24 Antigen Test
2.7.5 Antigen-Antibody Immunoassay
2.7.6 Polymerase Chain Reaction Test
2.7.7 HIV Home-Testing Kit
2.8 Disease Staging
2.8.1 WHO Clinical Staging
2.8.2 Centers for Disease Control and Prevention Classification System
2.8.3 Immunological Classification
2.9 Co-morbidities and Complications
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitor
2.11.2 Non-Nucleoside Reverse Transcriptase Inhibitor
2.11.3 Entry Inhibitor
2.11.4 Integrase Inhibitor
2.11.5 HIV-1 Protease Inhibitor
2.11.6 Pharmacokinetic Enhancer
2.12 Treatment Algorithm
To Get Download Full Report with TOC: http://www.marketresearchreports.biz/analysis/193009
3 Marketed Products
3.1 Therapeutic Landscape
3.1.1 Multi-class Combinations
3.1.2 Nucleotide Reverse Transcriptase Inhibitors
3.1.3 Non-Nucleoside Reverse Transcriptase Inhibitor
3.1.4 HIV Protease Inhibitor
3.1.5 Integrase Inhibitor
3.1.6 Entry Inhibitor
3.2 Comparative Efficacy and Safety
3.2.1 Multi-class Combination
3.2.2 Nucleotide Reverse Transcriptase Inhibitor
3.2.3 Non-Nucleotide Reverse Transcriptase Inhibitor
3.2.4 HIV Protease Inhibitor
3.2.5 Integrase Inhibitor
3.2.6 Entry Inhibitor
3.3 Unmet Need
4 Pipeline for HIV
4.1 Overall Pipeline
4.2 Mechanism of Action in HIV Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate of Developmental Pipeline
4.3.2 Clinical Trial Sizes
4.3.3 Clinical Trial Duration
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Candidates in Pipeline
4.4.1 572-Trii (dolutegravir + abacavir sulfate + lamivudine) – Shionogi-ViiV Healthcare
4.4.2 Atazanavir sulfate + cobicistat – Bristol-Myers Squibb, Gilead
4.4.3 Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide – Gilead
4.4.4 Apricitabine – Avexa
4.4.5 Remune (IR-103) – Immune Response BioPharma
4.4.6 Censavudine – Bristol-Myers Squibb
4.4.7 Elvucitabine – Achillion
4.4.8 Cenicriviroc – Tobira Therapeutics
4.5 Heat Map and Competitor Matrix for HIV Pipeline Products
5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries in Europe
5.1.4 Japan
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers
6 Deals and Strategic Consolidations
6.1 Major Co-development Deals
6.1.1 DFH Pharma Enters Agreement with Hetero Drugs
6.1.2 GlaxoSmithKline Enters Agreement with Concert Pharmaceuticals
6.1.3 GenVec Enters Agreement with SAIC-Frederick
6.2 Major Licensing Deals
6.2.1 Merck Enters Agreement with Chimerix
6.2.2 Bristol-Myers Squibb Enters Agreement with Gilead
6.2.3 Japan Tobacco Enters Agreement with Gilead
6.2.4 Gilead Enters Agreement with Tibotec
6.2.5 Benitec Enters Agreement with Calimmune
6.2.6 Bristol-Myers Squibb Enters Agreement with Oncolys BioPharma
7 Appendix 1
Latest Report:
Gastric Cancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019 : http://www.marketresearchreports.biz/analysis-details/gastric-cancer-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Gastric cancer refers to the cancer arising from lining of stomach. It may lead to uncontrolled growth of malignant cells that originate in stomach tissue and forms a tumor in any part of the stomach. Mainly there are five types of gastric cancer namely adenocarcinoma, squamous cell cancer, lymphoma, gastrointestinal stromal tumors, neuroendocrine tumors. From all these types, adenocarcinoma types of cancer originates from the innermost lining of stomach and accounts for more than 90% of all gastric tumors. Dysphagia, frequent burping, heartburn, stomachache are some of the early stomach cancer symptoms. The drugs of gastric cancers works on extracellular and intracellular domain of HER2 receptor of stomach and continuously suppress the tumor proliferation that lead to cell stasis and death.
According to World Health Organization, approximately 800,000 cancer related deaths are caused by gastric cancer every year and American Cancer Society estimated that in 2013 approximately 21,600 cases of gastric cancer will be diagnosed. This increasing incidences of gastric cancer drives the market of gastric cancer drugs. In addition, introduction of new therapies like Taxotere, Xeloda and Herceptin are also expected to propel the demand for gastric cancer drugs. However, less number of commercially available drugs for the treatment of gastric cancer may hinder the market growth.
The global Gastric Cancer Drugmarket is categorized based on the following:
By Class of Drugs
Doxorubicin Hydrochloride
Fluorouracil
Trastuzumab
Mitomycin C
Docetaxel
Imatinib
Sunitinib
Geographically, China and Japan dominate the global gastric cancer drug market due to large patient base and rise in treatment seeking population in these regions.Also, with the rise in geriatric population the number of people diagnosed with gastric cancer also increases which ultimately impacts the growth of gastric cancer drugs in these markets. The market of gastric cancer drug in North America and Europeholds a strong growth as the key players are domiciled in these regions. With the rise in uptake of gastric cancer drugs namely is Herceptin, Erbitux and Afitnitor also accentuates the growth of these drugs in the North American and European market.However, the total number of newly diagnosed patients are five times greater in China and Japan than the United States, making Japanese and Chinese market commercially attractive for developers.
Sample Request : http://www.marketresearchreports.biz/sample/toc/192741
Botanical And Plant Derived Drugs Market - Global Industry Analysis, Size, Share, Growth, Trend And Forecast 2013 – 2019: http://www.marketresearchreports.biz/analysis-details/botanical-and-plant-derived-drugs-market-global-industry-analysis-size-share-growth-trend-and-forecast-2013-2019
Botanical drugs are drugs develop through botanical drug and research pathway, whereas plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. These botanical products are intended for use in the mitigation, cure, diagnosis and treatment or prevention of diseases in humans.
The global market for botanical and plant derived drugs is witnessing a significant growth over recent years due to rising usage of these drugs in different parts of the world. Increased focus of research institutes and clinical trial studies, price reduction and improved technological and sociological development are major driving factors for the growth of this market. However, low acceptance of these drugs for the treatment of lethal diseases is a major restraint for the market. On the other hand, rising number of FDA approved botanical drugs and their application is a key opportunity for the market. Some of the major classes of botanical and plant derived drugs are Tarpenes and Steroids, Glycosides, Ergot Alkaloids, Morphine Alkaloids and Vinca Alkaloids.
Global market of botanical and plant derived drugs market is primarily divided into two segments: based on geography and based on therapeutic applications. The U.K., Germany and France are major countries of the European Region. On the basis of therapeutic application, the market is segmented into hormone related disease therapy, infectious diseases, pain and central nervous system disorders, cardiovascular and metabolic diseases, respiratory and oncology diseases treatment. Some of the major players operating in the market are Abott Laboratories, Bayer Healthcare, Bionova, Bristol Myers and Curapharm.
Sample Request : http://www.marketresearchreports.biz/sample/toc/192763
Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: sales@marketresearchreports.biz
The leading business intelligence provider GBI Research has released its latest research report, entitled “HIV Therapeutics Market to 2019 – Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth”. The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research found that the HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012–2019 forecast period to reach $16.3 billion.
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/hiv-therapeutics-market-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-market-growth
Scope
The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV.
The report covers and includes:
• A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and diagnosis
• In-depth analysis of major glucose-lowering drugs for HIV, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
• Comprehensive review of the pipeline for HIV therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
• Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
• Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy, Spain and Canada
• Discussion of the drivers and barriers for market growth
Reasons to Buy
Browse Full Report With TOC: http://www.marketresearchreports.biz/sample/sample/193009
The report will enhance your decision-making capability. It will allow you to:
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
• Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
• Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Route of HIV Transmission
2.3 Etiology
2.4 Classification of HIV-1 Subtypes
2.5 Pathophysiology 12
2.5.1 HIV-1 Replication Cycle
2.5.2 Mechanism of CD4 T-Cell Death
2.5.3 Latent Infection and Viral Persistence
2.6 Symptoms
2.7 Diagnosis
2.7.1 HIV Antibody Assay
2.7.2 Rapid HIV Antibody Test
2.7.3 Western Blot
2.7.4 HIV p24 Antigen Test
2.7.5 Antigen-Antibody Immunoassay
2.7.6 Polymerase Chain Reaction Test
2.7.7 HIV Home-Testing Kit
2.8 Disease Staging
2.8.1 WHO Clinical Staging
2.8.2 Centers for Disease Control and Prevention Classification System
2.8.3 Immunological Classification
2.9 Co-morbidities and Complications
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitor
2.11.2 Non-Nucleoside Reverse Transcriptase Inhibitor
2.11.3 Entry Inhibitor
2.11.4 Integrase Inhibitor
2.11.5 HIV-1 Protease Inhibitor
2.11.6 Pharmacokinetic Enhancer
2.12 Treatment Algorithm
To Get Download Full Report with TOC: http://www.marketresearchreports.biz/analysis/193009
3 Marketed Products
3.1 Therapeutic Landscape
3.1.1 Multi-class Combinations
3.1.2 Nucleotide Reverse Transcriptase Inhibitors
3.1.3 Non-Nucleoside Reverse Transcriptase Inhibitor
3.1.4 HIV Protease Inhibitor
3.1.5 Integrase Inhibitor
3.1.6 Entry Inhibitor
3.2 Comparative Efficacy and Safety
3.2.1 Multi-class Combination
3.2.2 Nucleotide Reverse Transcriptase Inhibitor
3.2.3 Non-Nucleotide Reverse Transcriptase Inhibitor
3.2.4 HIV Protease Inhibitor
3.2.5 Integrase Inhibitor
3.2.6 Entry Inhibitor
3.3 Unmet Need
4 Pipeline for HIV
4.1 Overall Pipeline
4.2 Mechanism of Action in HIV Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate of Developmental Pipeline
4.3.2 Clinical Trial Sizes
4.3.3 Clinical Trial Duration
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Candidates in Pipeline
4.4.1 572-Trii (dolutegravir + abacavir sulfate + lamivudine) – Shionogi-ViiV Healthcare
4.4.2 Atazanavir sulfate + cobicistat – Bristol-Myers Squibb, Gilead
4.4.3 Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide – Gilead
4.4.4 Apricitabine – Avexa
4.4.5 Remune (IR-103) – Immune Response BioPharma
4.4.6 Censavudine – Bristol-Myers Squibb
4.4.7 Elvucitabine – Achillion
4.4.8 Cenicriviroc – Tobira Therapeutics
4.5 Heat Map and Competitor Matrix for HIV Pipeline Products
5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries in Europe
5.1.4 Japan
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers
6 Deals and Strategic Consolidations
6.1 Major Co-development Deals
6.1.1 DFH Pharma Enters Agreement with Hetero Drugs
6.1.2 GlaxoSmithKline Enters Agreement with Concert Pharmaceuticals
6.1.3 GenVec Enters Agreement with SAIC-Frederick
6.2 Major Licensing Deals
6.2.1 Merck Enters Agreement with Chimerix
6.2.2 Bristol-Myers Squibb Enters Agreement with Gilead
6.2.3 Japan Tobacco Enters Agreement with Gilead
6.2.4 Gilead Enters Agreement with Tibotec
6.2.5 Benitec Enters Agreement with Calimmune
6.2.6 Bristol-Myers Squibb Enters Agreement with Oncolys BioPharma
7 Appendix 1
Latest Report:
Gastric Cancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019 : http://www.marketresearchreports.biz/analysis-details/gastric-cancer-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Gastric cancer refers to the cancer arising from lining of stomach. It may lead to uncontrolled growth of malignant cells that originate in stomach tissue and forms a tumor in any part of the stomach. Mainly there are five types of gastric cancer namely adenocarcinoma, squamous cell cancer, lymphoma, gastrointestinal stromal tumors, neuroendocrine tumors. From all these types, adenocarcinoma types of cancer originates from the innermost lining of stomach and accounts for more than 90% of all gastric tumors. Dysphagia, frequent burping, heartburn, stomachache are some of the early stomach cancer symptoms. The drugs of gastric cancers works on extracellular and intracellular domain of HER2 receptor of stomach and continuously suppress the tumor proliferation that lead to cell stasis and death.
According to World Health Organization, approximately 800,000 cancer related deaths are caused by gastric cancer every year and American Cancer Society estimated that in 2013 approximately 21,600 cases of gastric cancer will be diagnosed. This increasing incidences of gastric cancer drives the market of gastric cancer drugs. In addition, introduction of new therapies like Taxotere, Xeloda and Herceptin are also expected to propel the demand for gastric cancer drugs. However, less number of commercially available drugs for the treatment of gastric cancer may hinder the market growth.
The global Gastric Cancer Drugmarket is categorized based on the following:
By Class of Drugs
Doxorubicin Hydrochloride
Fluorouracil
Trastuzumab
Mitomycin C
Docetaxel
Imatinib
Sunitinib
Geographically, China and Japan dominate the global gastric cancer drug market due to large patient base and rise in treatment seeking population in these regions.Also, with the rise in geriatric population the number of people diagnosed with gastric cancer also increases which ultimately impacts the growth of gastric cancer drugs in these markets. The market of gastric cancer drug in North America and Europeholds a strong growth as the key players are domiciled in these regions. With the rise in uptake of gastric cancer drugs namely is Herceptin, Erbitux and Afitnitor also accentuates the growth of these drugs in the North American and European market.However, the total number of newly diagnosed patients are five times greater in China and Japan than the United States, making Japanese and Chinese market commercially attractive for developers.
Sample Request : http://www.marketresearchreports.biz/sample/toc/192741
Botanical And Plant Derived Drugs Market - Global Industry Analysis, Size, Share, Growth, Trend And Forecast 2013 – 2019: http://www.marketresearchreports.biz/analysis-details/botanical-and-plant-derived-drugs-market-global-industry-analysis-size-share-growth-trend-and-forecast-2013-2019
Botanical drugs are drugs develop through botanical drug and research pathway, whereas plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. These botanical products are intended for use in the mitigation, cure, diagnosis and treatment or prevention of diseases in humans.
The global market for botanical and plant derived drugs is witnessing a significant growth over recent years due to rising usage of these drugs in different parts of the world. Increased focus of research institutes and clinical trial studies, price reduction and improved technological and sociological development are major driving factors for the growth of this market. However, low acceptance of these drugs for the treatment of lethal diseases is a major restraint for the market. On the other hand, rising number of FDA approved botanical drugs and their application is a key opportunity for the market. Some of the major classes of botanical and plant derived drugs are Tarpenes and Steroids, Glycosides, Ergot Alkaloids, Morphine Alkaloids and Vinca Alkaloids.
Global market of botanical and plant derived drugs market is primarily divided into two segments: based on geography and based on therapeutic applications. The U.K., Germany and France are major countries of the European Region. On the basis of therapeutic application, the market is segmented into hormone related disease therapy, infectious diseases, pain and central nervous system disorders, cardiovascular and metabolic diseases, respiratory and oncology diseases treatment. Some of the major players operating in the market are Abott Laboratories, Bayer Healthcare, Bionova, Bristol Myers and Curapharm.
Sample Request : http://www.marketresearchreports.biz/sample/toc/192763
Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: sales@marketresearchreports.biz
No comments:
Post a Comment